SPRYCEL (dasatinib) for Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia - Cancer Therapy Advisor

SPRYCEL (dasatinib) for Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for SPRYCEL (dasatinib), indicated for chronic myeloid leukemia and acute lymphoblastic leukemia.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 9: Use in Specific Populations
Slide 11: Clinical Pharmacology
Slide 15: Warnings and Precautions
Slide 20: Clinical Safety and Efficacy
Slide 37: Drug Storage and Supply
Slide 39: References

Next hm-slideshow in Slides